Epigral Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
EPIGRAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Epigral Limited reported annual revenue of Rs 2,527 crore for FY26, slightly down from Rs 2,550 crore in FY25, representing a marginal 0.9% revenue decline. Profit after tax fell 6.6% to Rs 333 crore from Rs 357 crore in the previous year. The company saw significant increases in finance costs (up 35% to Rs 72 crore) and depreciation (up 27% to Rs 168 crore). A one-time deferred tax credit of Rs 76 crore was recognized due to adoption of lower tax rates under Section 115BAA. Capital work-in-progress more than tripled to Rs 451 crore, indicating major expansion investments. The board recommended a final dividend of Rs 5 per share. Auditors issued unmodified opinions on both standalone and consolidated results.
The slight revenue and profit decline amid rising finance costs may concern investors, though the clean audit opinion and strong operating cash flow of Rs 436 crore provide some comfort. The massive increase in capital work-in-progress signals significant future capacity expansion that could drive future growth.